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Abstract
Formation of the cardiac valves is an essential component of cardiovascular development.
Consistent with the role of the bone morphogenetic protein (BMP) signaling pathway in car-
diac valve formation, embryos that are deficient for the BMP regulator BMPER (BMP-bind-
ing endothelial regulator) display the cardiac valve anomaly mitral valve prolapse. However,
how BMPER deficiency leads to this defect is unknown. Based on its expression pattern in
the developing cardiac cushions, we hypothesized that BMPER regulates BMP2-mediated
signaling, leading to fine-tuned epithelial-mesenchymal transition (EMT) and extracellular
matrix deposition. In the BMPER-/- embryo, EMT is dysregulated in the atrioventricular and
outflow tract cushions compared with their wild-type counterparts, as indicated by a signifi-
cant increase of Sox9-positive cells during cushion formation. However, proliferation is not
impaired in the developing BMPER-/- valves. In vitro data show that BMPER directly binds
BMP2. In cultured endothelial cells, BMPER blocks BMP2-induced Smad activation in a
dose-dependent manner. In addition, BMP2 increases the Sox9 protein level, and this
increase is inhibited by co-treatment with BMPER. Consistently, in the BMPER-/- embryos,
semi-quantitative analysis of Smad activation shows that the canonical BMP pathway is sig-
nificantly more active in the atrioventricular cushions during EMT. These results indicate
that BMPER negatively regulates BMP-induced Smad and Sox9 activity during valve devel-
opment. Together, these results identify BMPER as a regulator of BMP2-induced cardiac
valve development and will contribute to our understanding of valvular defects.
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Introduction
The cardiac valves promote unidirectional flow through the heart, and valve defects are among
the most common congenital heart defects [1]. The valves form from an initial swelling in the
outflow tract and the atrioventricular canal [2]. The overlying myocardium induces epithelial-
mesenchymal transition (EMT) in the underlying endothelial layer, and a subset of these endo-
thelial cells undergoes EMT to populate space between the layers to form cushions. This mes-
enchymal population is highly proliferative and fills the space between the myocardium and
endocardium. As the atrioventricular cushions are populated, they give rise to the mitral and
tricuspid valves; in contrast, the outflow tract cushions, which give rise to the semilunar valves,
are also populated by migrating cardiac neural crest-derived cells. Once populated, these cush-
ions remodel and elongate, and the extracellular matrix is remodeled; these steps transform the
cushions into the mature valves.
One of the earliest signals involved in cushion formation is bone morphogenetic protein
(BMP) 2. BMP2 is secreted from the myocardium, and the endocardium expresses BMP recep-
tor 1A [3]. In the developing cushions, BMP2 is sufficient to induce EMT [4] and induces the
transcription factors Snail [5], and Twist1 and Msx1/2 [6]. Additionally, BMP2 also induces
the transcription factor Sox9 in another population, the neural crest, that also undergoes EMT
[7]. All of these transcription factors are required for EMT, and many of them are associated
with valve malformations [3]. In addition to regulating EMT in the early stages of cushion for-
mation, Sox9 also promotes elongation and maturation of the mitral and tricuspid valves [8];
however, whether BMP2 promotes this later Sox9 expression is unknown.
Despite the importance of BMP2 in the early stages of cardiac valve development, only
intracellular BMP repressor Smad6 has yet been correlated with cardiac valve abnormalities in
the Online Mendelian Inheritance in Man database. This discrepancy is highly surprising due
to how common these anomalies are and suggests that the BMP pathway is tightly regulated
during cardiac development. The BMP pathway can be regulated in numerous ways, including
through extracellular proteins. However, the role of BMP regulators in cardiac valve develop-
ment is understudied. The BMP antagonist noggin can block EMT in excised atrioventricular
cushions [9], and noggin is expressed in the myocardium surrounding the developing cushions
at E9.5 [10]. Correspondingly, the noggin knockout mouse displays hyperplastic atrioventricu-
lar and outflow tract cushions [10]. In the chick, BMP inhibitor follistatin is expressed in the
endocardium overlying the developing cardiac cushions [11], but its specific role is unknown.
Previous work in the Patterson laboratory identified a cardiac valve anomaly similar to
mitral valve prolapse in mice that are homozygous null for the BMP regulator BMPER (BMP-
binding endothelial regulator) [12]. Further, BMPER is expressed in the cardiac valve mesen-
chyme at E13.5-E14.5 [13], and BMPER has been indirectly shown to interact with BMP2 [14].
Thus, we hypothesized that BMPER modulates BMP2-dependent cardiac valve development.
In this study, we show that BMPER is expressed in the developing cardiac cushions and specifi-
cally inhibits the canonical BMP intracellular pathway. Further, BMP2-induced EMT is dysre-
gulated in BMPER-/- embryos in a stage-dependent manner, highlighting how tightly the BMP
pathway is regulated during EMT. Together, these results support the importance of BMP reg-
ulation during cardiac valve development.
Materials and Methods
Mice
The BMPER-/- mouse was created previously [15] and is maintained on a mixed C57Bl6/129
background. Because the BMPER-/- embryo is non-viable, embryos were obtained through
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BMPER+/- timed pregnancies. All experiments were approved by the Institutional Animal Care
and Use Committee at the University of North Carolina at Chapel Hill and Baylor College of
Medicine.
Antibodies
The following antibodies were used for immunohistochemistry, co-immunoprecipitation, or
Western blot analysis: MF-20 (Cat. No. MF-20; Developmental Studies Hybridoma Bank, Iowa
City, IA); PECAM (Cat. No. 553370) and Nfat-c1 (Cat. No. 553370; Becton-Dickinson, San
Jose, CA); Sox9 (Cat. No. sc-20095; Santa Cruz Biotechnology, Santa Cruz, CA); Smad1 (Cat.
No. 9743S) and phospho-Smad1,5,8 (pSMAD, Cat. No. 13820S; Cell Signaling Technology,
Danvers, MA); anti-Crossveinless-2 (referred to as anti-BMPER, Cat. No. AF2299; R&D Sys-
tems, Minneapolis, MN); anti-BMP2 (Cat. No. ab14933; Abcam, Cambridge, MA); phalloidin-
Texas Red (Cat. No. T7471; Molecular Probes, Grand Island, NY); and anti-ß-actin (Cat. No.
A2228; Sigma, St. Louis, MO).
Histology and immunohistochemistry
For immunohistochemical analyses, embryos were harvested in phosphate-buffered saline
(PBS) or 0.1 M Tris buffer (pH 7.6), fixed in 4% formaldehyde overnight at 4°C, washed in PBS
or 0.1 M Tris buffer, and processed for frozen sectioning. Unless indicated, immunohistochem-
istry was performed as described in Waldo et al. [16]. Microwave antigen retrieval using 10
mM citrate buffer (pH 6.0) was required for Nfat-c1, Sox9, and pSMAD. pSMAD immunohis-
tochemistry and semi-quantitative analysis was performed as described in Dyer et al. [13,17].
We processed each litter as a batch to ensure similar conditions throughout the experiment.
Within each batch of slides, the slides were examined using identical photography and imaging
conditions, and the relative fluorescence intensity in each batch was calculated with respect to
the average fluorescence intensity of the littermate wild-types. BMPER immunohistochemistry
was performed as described in Zakin et al. [18]. DAPI (Invitrogen, Grand Island, NY) was used
as a nuclear counterstain. Slides were examined and imaged as described in Dyer et al. [13].
BMPER-BMP2 co-immunoprecipitation
Co-immunoprecipitations were performed using recombinant BMPER and BMP2 (both from
R&D Systems) as previously described [14]. In brief, beads were conjugated with antibodies
recognizing BMPER, BMP2, or the respective IgG controls (goat and rabbit). After incubating
antibody-conjugated beads with different combinations of recombinant protein, the beads
were isolated and prepared for Western blot.
BMP activity assay
To determine how BMPER modulated BMP2 activity, mouse cardiac-derived endothelial cells
(MECs) were serum starved for 24 h and treated with or without 0.6 nM recombinant BMP2
and increasing doses of recombinant BMPER (0–9.6 nM). Cell lysates were collected after 30
min in Tris-sodium chloride-Tween 20 buffer and analyzed as described in Kelley et al. [15].
All treatments were performed in quadruplicate.
Western blot analysis
Proteins samples were separated on 4–12% bis-Tris gels and transferred to PVDF membranes;
the resulting membranes were blotted for the indicated proteins. For the BMP activity assay,
total Smad and β-actin were used as loading controls. Band density was calculated using ImageJ
BMPER and Valve Development
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software (www.nih.gov), was normalized to the loading controls, and is presented as the fold-
change compared with the untreated samples.
Statistical analysis
Quantitative data were compared using unpaired Student’s t-test with equal variances in Excel,
one or two-way ANOVA and multiple comparisons in Prism. A p-value<0.05 was considered
statistically significant.
Results
BMPER is expressed throughout the developing cushions
Because the BMP pathway promotes normal valve development [3] and the BMPER-/- embryo
presents with mitral valve anomalies at E18.5 [12], we wanted to assess whether BMPER affects
the early stages of valve formation. Thus, BMPER protein expression was examined between
E9.5 and E11.5. At E9.5, the mesenchymal cells populating the atrioventricular cushions have
begun expressing BMPER, whereas no expression is present yet in the outflow tract cushions
(Fig 1A and 1D). By E10.5, the mesenchymal cells that populate both the atrioventricular and
outflow tract cushions express BMPER (Fig 1B and 1E), and expression is maintained through
E11.5 in both sets of cushions (Fig 1C and 1F). As expected, no BMPER protein is detected in
BMPER-/- embryos (data not shown and [13]). Interestingly, BMPER expression in the overly-
ing endothelial layer appears much weaker with respect to the mesenchyme. BMPER remains
expressed in the mesenchymal cells through at least E14.5 [12]. BMPER’s more robust expres-
sion within the mesenchyme suggests that it does not affect the initiation of EMT but may have
later effects during EMT.
EMT is dysregulated in BMPER-/- embryos
At E18.5, the BMPER-/- embryo displays a mitral valve phenotype that is consistent with mitral
valve prolapse [12]. Thus, in combination with the increased expression of BMPER in the
developing cushions when EMT takes place and BMP2’s critical role in EMT [4], we hypothe-
sized that BMPER would affect EMT. We evaluated the expression of two EMT markers: Nfat-
c1, which is an early marker of EMT [20], and Sox9, which is a late marker of EMT and a
known BMP2 target [7]. In the atrioventricular cushions, Nfat-c1 expression was observed in
the overlying endocardium at E9.5–11.5 in both the wild-type and BMPER-/- embryos, with no
apparent differences (Fig 2A–2F, red signal). In contrast, non-significantly fewer Sox9-positive
cells were initially observed in the BMPER-/- atrioventricular cushions at E9.5 (Fig 2B, com-
pared with 2A, green signal, and 2G). However, by E10.5, significantly more Sox9-positive cells
were present in the BMPER-/- atrioventricular cushions (Fig 2D, green signal, and 2G). Inter-
estingly, although the total number of Sox9-positive cells increased at E10.5, the percentage of
mesenchymal cells that expressed Sox9 non-significantly decreased at E10.5 (82.5% in the
BMPER-/- vs. 86.8% in the wild-type atrioventricular cushions), indicating that more Sox9-ne-
gative mesenchymal cells were also present in the BMPER-/- atrioventricular cushions. The
increase in total Sox9-positive cells was short-lived; between E10.5 and E11.5, the number of
wild-type Sox9-positive cells increased greatly, whereas the BMPER-/- Sox9-positive cells
showed only a slight increase, leading to fewer overall Sox9-positive mesenchymal cells in the
BMPER-/- atrioventricular cushions compared with the wild-type cushions (Fig 2E and 2F,
green signal and 2G). Additionally, the percentage of mesenchymal cells that were Sox9-posi-
tive was also significantly decreased (72.2% in the BMPER-/- vs. 92.3% in the wild-type cush-
ions, p<0.01), suggesting that a subset of mesenchymal cells have prematurely stopped
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expressing Sox9. A similar, though non-significant, pattern was observed in the outflow tract
cushions (Fig 2H–2N). The disruption of Sox9 expression, but not Nfat-c1 expression, is con-
sistent with BMPER’s expression within the forming mesenchymal cells but exclusion from the
overlying endocardium. Together, these data suggest that EMT is dysregulated in the absence
of BMPER but that a secondary mechanism quickly compensates for the lack of BMPER.
Mesenchymal proliferation is not regulated by BMPER
As a potential mechanism to explain the sudden increase in Sox9-positive cells in the
BMPER-/- atrioventricular cushions at E10.5, we examined proliferation at E9.5-E11.5. Surpris-
ingly, though, no differences were observed in the proliferation rates in the BMPER-/- atrioven-
tricular cushions compared with their wild-type counterparts at any time point examined (Fig
3A–3G). Additionally, no statistically significant differences in the proliferation rate were
observed between genotypes in the outflow tract cushions at any time point examined; how-
ever, there was a non-significant increase at E9.5 in the BMPER-/- outflow tract cushions (Fig
3H–3N). These results suggest that the increase in Sox9-positive cell number at E10.5 is not
due to an increase in cell proliferation. Other unknown mechanisms involved in this process
remain to be determined.
BMPER interacts with BMP2 and modulates BMP2-mediated signaling
Previous work has directly shown that BMPER interacts with BMP4 and indirectly shown that
BMPER also interacts with BMP2 [14]. Because BMP2 is the major BMP involved in cardiac
Fig 1. BMPER is expressed in the developing cardiac cushions. BMPER protein expression was evaluated in the atrioventricular cushions (AVC; A-C)
and outflow tract cushions (OFT; D-F) at E9.5 (A, D), E10.5 (B, E), and E11.5 (C, F). (A-C) BMPER protein is strongly expressed in the mesenchymal cells
that populate the AVCs and is expressed at very low levels in the overlying endocardial layer. (D-F) Consistent with epithelial-mesenchymal transition (EMT)
occurring slightly later in the OFT cushions compared with the AVCs (A-C), no BMPER-positive cells are observed in the OFT at E9.5 (D). As EMT
progresses (E-F), the OFT cushions fill with BMPER-positive mesenchymal cells. Scale bar in D = 60 μm in panels A, B, D, and E and = 120 μm in panels C
and F. A, common atrium; V, common ventricle; LA, left atrium; LV, left ventricle.
doi:10.1371/journal.pone.0139209.g001
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cushion development by inducing Sox9 [6], we tested the direct interaction of BMPER-BMP2
using co-immunoprecipitation with recombinant proteins BMPER and BMP2. As a positive
control, the BMP2 antibody and the BMPER antibody both successfully immunoprecipitated
BMP2 and BMPER, respectively (Fig 4A). In the presence of both proteins, both antibodies
could immunoprecipitate both proteins (Fig 4A), thus indicating that BMPER and BMP2
directly interact in vitro.
Fig 2. EMT is dysregulated in the BMPER-/- cushions. EMTmarkers Nfat-c1 (red) and Sox9 (green) were assessed in the atrioventricular cushions (AVCs;
A-G) and outflow tract (OFT) cushions (H-N) at E9.5-E11.5. In wild-type (A, C, E) and BMPER-/- (B, D, F) AVCs at E9.5 (A, B), E10.5 (C, D), and E11.5 (E, F),
Nfat-c1 expression appears identical between genotypes at each time point. In contrast, BMPER-/- embryos tend to have fewer Sox9-positive cells at E9.5 (B;
p<0.1, quantified in G). By E10.5, the number of Sox9-positive cells is significantly higher in the BMPER-/- AVCs (D; *, p<0.01) compared with the wild-type
AVCs (C). This pattern is not maintained, with a non-significant reduction in Sox9-positive cells present in the BMPER-/- AVCs by E11.5 (compare F with wild-
type in E). (G) The number of Sox9-positive cells was counted in 2–4 sagittal sections, and the two most populated AVCs per embryo were averaged and
used to compare how the cushions were populated. n = 6, 5, and 4WT AVCs (black bars) and 6, 7, and 4 BMPER-/- AVCs (white bars) at E9.5, E10.5, and
E11.5, respectively. (H-N) Nfat-c1 expression in the OFT cushions appears identical between genotypes at each time point. Though not statistically
significant, BMPER-/- OFT cushions show the same pattern of Sox9-positive cell counts as the AVCs, with a tendency toward fewer Sox9-positive cells at
E9.5 (I compared with WT in H, quantified in N), more Sox9-positive cells at E10.5 (K compared with WT in J), and fewer Sox9-positive cells at E11.5 (M
compared with WT in L). (N) The number of Sox9-positive cells was counted as describe in (G). n = 6, 7, and 4WT OFT cushions (black bars) and 6, 8, and 4
BMPER-/- OFT cushions (white bars) at E9.5, E10.5, and E11.5, respectively. Student’s t-test was used to compare means between genotypes. Scale bars in
C and D = 120 μm and apply to A-F and H-M.
doi:10.1371/journal.pone.0139209.g002
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Because BMPER regulates BMP4-induced activity [15] and BMPER and BMP2 interact in
vitro, we wanted to determine what the effect of BMPER was on BMP2-induced signaling and
Sox9 induction. Ideally, these effects would have been tested using ex vivo cultured cushions or
embryonic mesenchymal cells. Due to technical difficulties with the ex vivo collagen gel tech-
nique and to allow for more similar comparisons with previous BMPER research [15,19],
MECs were utilized for these experiments. MECs were treated with a fixed concentration of
BMP2 and increasing concentrations of BMPER. Unlike BMPER’s ability to both promote and
Fig 3. Proliferation is normal in the BMPER-/- cushions. Proliferation was assessed in the atrioventricular cushions (AVCs) and outflow tract (OFT)
cushions. Proliferative cells were detected via phosphohistone H3 expression (green), and sagittal sections were colabeled with the myocardial marker
MF20 (red) and nuclear marker DAPI (blue). For each sample, all mesenchymal cells in at least 3 sections or a minimum of 100 cells were counted. (A-G)
Wild-type (A, C, E) and BMPER-/- (B, D, F) AVCs were evaluated at E9.5 (A, B), E10.5 (C, D), and E11.5 (E, F). (A, B) At E9.5, no significant differences were
observed between genotypes. (C, D) By E10.5, the proliferation remained similar in both the BMPER-/- and wild-type AVCs. (E, F) By E11.5, the proliferation
rate increased similarly in both genotypes. (G) The proliferation rates for each group were quantified. n = 2, 4, and 3 for wild-type AVCs and 2, 5, and 3 for
BMPER-/- AVCs at E9.5, E10.5, and E11.5, respectively. (H-N) Wild-type and BMPER-/- OFT cushions were evaluated in the same manner. (H, I) At E9.5,
proliferation was increased, though not significantly, in the OFT cushions of BMPER-/- embryos compared with wild-type embryos. (J, K) By E10.5, the
proliferation rate decreased in the BMPER-/- OFT cushions and was comparable to that in the wild-type OFT cushions. (L, M) As EMT ended and the OFT
cushions entered the proliferative phase, the proliferation rate increased similarly in both genotypes. (N) The proliferation rates for each group were
quantified. n = 2, 4, and 3 for wild-type OFT cushions and 2, 5, and 3 for BMPER-/- OFT cushions at E9.5, E10.5, and E11.5, respectively. Scale bars in A, B,
H, and I = 100 μm; scale bars in C, D, J, and K = 110 μm and apply to E, F, L, and M.
doi:10.1371/journal.pone.0139209.g003
BMPER and Valve Development
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inhibit BMP4, BMPER serves only as an inhibitor of BMP2-induced Smad phosphorylation
(Fig 4B). In response to BMP2 treatment alone, Smad phosphorylation increases quickly in
MECs, and this response is inhibited exponentially by increasing concentrations of BMPER. In
addition, BMP2 treatment increases Sox9 protein expression as early as one hour after stimula-
tion (Fig 4C), consistent with the published data [7]. More interestingly, BMPER co-treatment
significantly blocks Sox9 protein expression induced by BMP2 (Fig 4D). All these data indicate
that BMPER negatively regulates BMP2-induced Smad activity and Sox9 protein induction in
cultured MECs.
Because BMPER blocks BMP2 activity in cultured MECs, we hypothesized that Smad acti-
vation would increase in vivo in BMPER-/- embryos. When examining Smad phosphorylation
levels in BMPER-/- embryos with immunofluorescence using a relative fluorescence intensity
as an indicator of signaling activity, the pSmad intensity is non-significantly lower in the mes-
enchymal cells populating atrioventricular and outflow tract cushions compared with their
wild-type counterparts at E9.5 (Fig 4E and 4F). Additionally, no differences were observed
Fig 4. BMPER inhibits BMP2-induced signaling in the developing cushions. (A) Recombinant BMPER and BMP2 proteins were combined as indicated
and immunoprecipitated using an anti-BMPER antibody, an anti-BMP2 antibody, or the appropriate species-specific IgG antibody controls. As a loading
control, all unbound proteins in the supernatant were run in the Input lanes (right lanes). The anti-BMP2 antibody recognized recombinant BMP2 and co-
immunoprecipitated BMPERwhen both proteins were present. Similarly, the anti-BMPER antibody recognized recombinant BMPER and co-
immunoprecipitated BMP2 when both proteins were present. (B) BMPER inhibits BMP2-induced Smad1,5,8 phosphorylation (pSmad) in cultured endothelial
cells. MECs were treated with BMP2 and increasing doses of BMPER for 45 minutes. As expected, BMP2 treatment induced Smad phosphorylation (second
lane). With increasing concentrations of BMPER, the pSmad levels were exponentially reduced (R2 = 0.98). Data are presented as the fold change compared
with BMP2 treatment in the absence of BMPER treatment. Due to reduced signaling intensity when stripping and reprobing blots, β-actin was used as a
loading control instead of total Smad. (C) BMP2 increases the Sox9 protein level in cultured endothelial cells. MECs were treated with 0.6 nM BMP2 for the
indicated time periods. As expected, BMP2 treatment increased Sox9 protein levels. The arrow indicates the Sox9 protein band. N.S., not significant.
*p<0.05, compared with cells without treatment. n = 3. (D) BMPER inhibits BMP2-induced Sox9 protein expression in cultured endothelial cells. MECs were
treated with 0.6 nM BMP2 and 5 nM BMPER for 4 hours. BMPER co-treatment blocks BMP2-induced Sox9 protein expression. The arrow indicates the Sox9
protein band. N.S., not significant. *p<0.05, compared with control cells without treatment; #p<0.05, compared with cells with BMP2 treatment only. n = 3. (E)
BMPER affects downstream Smad1/5/8 activity in the developing atrioventricular cushions. At E9.5, BMPER-/- atrioventricular cushions display reduced
pSmad signals compared with their wild-type counterparts. However, by E10.5, the pSmad intensity increases in the BMPER-/- atrioventricular cushions
compared with the wild-type counterparts. This increase is not maintained, with reduced pSmad intensity in the BMPER-/- cushions by E11.5. Fluorescence
intensity is quantified on the right. (F) At E9.5, BMPER-/- outflow tract cushions display reduced pSmad compared with their wild-type counterparts. However,
by E10.5, the pSmad intensity increases in the BMPER-/- outflow tract cushions compared with the wild-type counterparts. This increase is not maintained,
with reduced pSmad intensity in the BMPER-/- cushions by E11.5. *p<0.05. Scale bar = 120 μm.
doi:10.1371/journal.pone.0139209.g004
BMPER and Valve Development
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between genotypes in the outflow tract myocardium, which does not express BMPER (data not
shown). However, this BMP activity pattern changes at E10.5, with significantly more intense
pSmad signals in the BMPER-/- cushions, as expected based on the in vitro data. By E11.5,
pSmad expression remains slightly reduced in the atrioventricular cushions of the BMPER-/-
embryos, and no changes are observed in the outflow tract cushions (Fig 4E and 4F). In combi-
nation with the in vitro data in MECs, these data suggest that BMPER regulates EMT process
by fine-tuning BMP activity at specific time points in these developing cushions. However,
additional regulatory components are likely also involved during valve development.
Discussion
The BMP pathway, particularly BMP2, is the major driving factor behind cardiac valve forma-
tion. The knockout of either BMP2 in the atrioventricular myocardium or receptor BMPR1 in
the endocardium leads to, respectively, a complete or nearly complete absence of cushion
development by blocking EMT [6,21–23]. Here, we show that the BMP regulator BMPER
inhibits BMP2-dependent signaling and fine-tunes normal valve development. In the absence
of BMPER, EMT in the cardiac cushions, particularly the atrioventricular cushions, is dysregu-
lated. We hypothesize that this dysregulation underlies the mitral valve prolapse observed in
E18.5 BMPER-/- embryos [12]. A similar valve phenotype is observed when BMP receptor II is
conditionally knocked out of the endocardium [24], and knockout of the BMP repressor
Smad6 leads to hyperplasia of the developing cushions [25]. These reports and our data sup-
port BMPER’s requisite role in this specific context.
The number of Sox9-positive cells in the BMPER-/- atrioventricular cushions increased dra-
matically between E9.5 and E10.5, compared with the more modest increase observed in the
wild-type atrioventricular cushions. These cell number data are particularly intriguing because
no increase in proliferation is observed in the BMPER-/- atrioventricular cushions at these
embryonic stages. Thus, how does the BMPER-/- embryo generate more Sox9-positive cells
than the wild-type embryo? Epicardial cells contribute to the parietal leaflets of the atrioven-
tricular valves through epithelial-mesenchymal transition, but this addition occurs at later
stages than those observed herein [26]. In the outflow tract, migrating cardiac neural crest-
derived cells [27] could explain these differences, but the BMPER-/- outflow tract cushions also
do not show differences in cell number. Neither of these populations thus appears to be a viable
mechanism, and the mechanism through which the BMPER-/- embryo recovers the number of
Sox9-positive atrioventricular cells remains elusive. One other possibility is related to the lower
proportion of mesenchymal cells that express Sox9 in the BMPER-/- atrioventricular cushions
at E11.5. Perhaps this increase in Sox9-negative cells drives the initiation of EMT in additional
epithelial cells, or perhaps some of the increased Sox9-positive cells observed at E10.5 prema-
turely turn off Sox9. Alternatively, BMP2 promotes the expression of repressor Smad6 to
restrict EMT [6]; thus, the absence of BMPER may lead to the up-regulation of Smad6 via
BMP2, halting EMT and leading to the reduced percentage of Sox9-positive mesenchymal cells
over time.
This ability to so carefully regulate cell number is dramatic and demonstrates the plasticity
of the early embryo. In similarly aged chicken embryos, previous work has shown that the ele-
vation of one signaling pathway can lead to compensatory upregulation in a regulatory path-
way within as little as 12 hours [17]. While in this prior study, the BMP pathway reduced
proliferation by regulating the Sonic hedgehog pathway, these results highlight the quickness
with which cardiac progenitors can respond to aberrant signaling. A similar regulatory event
may balance the elevated BMP signaling in the developing BMPER-/- valves.
BMPER and Valve Development
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Despite the temporal changes observed in the BMPER-/- atrioventricular cushions, our
results are consistent with BMPER playing a negative regulatory role in the BMP pathway in
this context. Knocking out the BMP antagonist noggin results in the opposite phenotype, with
excess EMT, overproliferation, and hyperplastic cardiac cushions [10], and knockout of the
repressor Smad6 similarly shows hyperplastic cardiac cushions [25]. The reduction of BMP4
signaling that occurs in a conditional knockout mouse lacking FGF receptors 1 and 2 in the
heart field progenitors is also accompanied by hypertrophic semilunar valves [28]. Our
BMPER deletion increased the Sox9-positive cell number at E10.5, suggesting hyperplasia (Fig
2). However, this increase is temporary and is not due to overproliferation. Additionally, the
number of Sox9-negative cells also increases by E11.5 in the atrioventricular cushions of the
BMPER-/- embryos. Together, these results suggest that additional mechanisms exist to com-
pensate BMPER activity and regulate EMT. Excess mesenchymal cells are also observed in the
Smad6 knockout mouse [25], supporting the role of the BMP pathway in capping the number
of cells that populate the cushions. These results suggest that only a narrow range of BMP sig-
naling can yield normal valves during development and highlight the necessity of understand-
ing how the BMP pathway is so carefully regulated. Further experimentation is required to
identify other components of the BMP regulatory complex and determine whether these regu-
lators are associated with human congenital valve anomalies.
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